PFS-02
Ready-to-use pre-filled syringe of Phenylephrine Hydrochloride
Phase 3Active
Key Facts
Indication
Ready-to-use pre-filled syringe of Phenylephrine Hydrochloride
Phase
Phase 3
Status
Active
Company
About Talphera
Talphera, formerly known as AcelRx Pharmaceuticals, has pivoted from acute pain management to a broader mission of developing products for medically supervised settings following the divestment of its acute pain product in 2023. The company's strategy centers on nafamostat, a serine protease inhibitor with anticoagulant, anti-inflammatory, and antiviral properties, creating a 'pipeline-in-a-product.' With Niyad granted FDA Breakthrough Device designation and top-line data expected by the end of 2025, Talphera is positioned to address a significant unmet need in renal care while exploring additional applications for its core asset.
View full company profile